Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

NCT ID: NCT03072589

Last Updated: 2020-06-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-30
• Study Completion Date: 2022-08-01

Brief Summary

This study will evaluate the maximum safe dose and duration of regadenoson (Lexiscan) that can be given to people who are having a lung transplant. Regadenoson will be given as a continuous IV infusion. All participants in the study will receive a regadenoson infusion beginning in the operating room during the lung transplant procedure. Participants will be assigned a certain dose of regadenoson to be given over a 12 or 24 hour period.

Detailed Description

Lung transplantation currently is one way to treat a variety of serious diseases and conditions such as emphysema, pulmonary fibrosis, and cystic fibrosis. Ischemia Reperfusion Injury (IRI) is a known problem that can happen during the first few days after a lung transplant. IRI can cause swelling of the lungs and low levels of oxygen. The most serious type of IRI can cause the transplanted lung to not work properly, it can even cause death. While new treatments and practices have been put into place to lower the chances of IRI, it is still a difficult problem to overcome after a lung transplant.

Medicines called Adenosine 2A receptors (A2AR) have been studied in animals with IRI for many years. Some of these studies suggest that with the use of A2AR medicines, the chance of IRI may be lowered or prevented. Regadenoson is an A2AR drug.

Conditions

Lung Transplant

Study Design

• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Regadenoson infusion

Dose escalation of Regadenoson infusion

Group Type: EXPERIMENTAL

Regadenoson infusion

Intervention Type: DRUG

Dose escalation of Regadenoson when given as an infusion

Interventions

Regadenoson infusion

Dose escalation of Regadenoson when given as an infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects must be undergoing a bilateral lung transplantation for end-stage lung disease and thus meet all criteria to be listed
• Male or female subject, 18 -75 years of age
• Subjects must sign a study specific informed consent prior to study entry
• Subjects must meet all of the following laboratory values:

1. hemoglobin ≥ 6 g/dL,

2. platelets > 75,000/mcL,

3. aspartate aminotransferase (AST/SGOT)/ alanine aminotransferase (ALT /SGPT) < 2.5 X institutional upper limit of normal,

4. serum creatinine < 1.5 mg/dL,

5. INR < 1.5, PTT < 40 seconds

Exclusion Criteria

• Subject requires preoperative extracorporeal membrane oxygenation (ECMO)
• Subject has second degree (Mobitz type I or II) or third-degree AV block or sinus node dysfunction
• Subject has history of a bleeding diathesis
• Subject has a history of clinically overt stroke within the past 3 years
• Subject has a history of severe hypertension not adequately controlled with anti-hypertensive medications (Systolic blood pressure ≥ 200 mmHg and/or Diastolic blood pressure ≥ 110 mmHg)
• Subjects who are receiving chronic anti-coagulation or anti-platelet therapy that would preclude surgery (prophylactic aspirin is acceptable)
• Subjects with a history of metastatic cancer
• Subjects with a history of seizure disorder
• Subjects who are receiving or have received within 30 days any other investigational agents
• Subjects who have received theophylline or aminophylline within 12 hours of study dosing

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

Christine Lau, MD

OTHER

Sponsor Role: lead

Responsible Party

Christine Lau, MD

Surgeon-in-Chief, Department of Surgery

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Christine Lau, MD

Role: PRINCIPAL_INVESTIGATOR

University of Maryland, Baltimore

Locations

University of Maryland

Baltimore, Maryland, United States

Site Status: RECRUITING

University of Virginia

Charlottesville, Virginia, United States

Site Status: ACTIVE_NOT_RECRUITING

Countries

United States

Central Contacts

Amanda Bartosic, MBA

Role: CONTACT

ABartosic@som.umaryland.edu

410-328-1641

Jennifer Phillips, RN

Role: CONTACT

jvp8a@virginia.edu

434-243-5435

Facility Contacts

Amanda Bartosic, MBA

Role: primary

ABartosic@som.umaryland.edu

410-328-1641

References

Lau CL, Beller JP, Boys JA, Zhao Y, Phillips J, Cosner M, Conaway MR, Petroni G, Charles EJ, Mehaffey JH, Mannem HC, Kron IL, Krupnick AS, Linden J. Adenosine A2A receptor agonist (regadenoson) in human lung transplantation. J Heart Lung Transplant. 2020 Jun;39(6):563-570. doi: 10.1016/j.healun.2020.02.003. Epub 2020 Feb 13.

Reference Type: DERIVED

PMID: 32503727 (View on PubMed)

Other Identifiers

1R01HL128492-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

UVA-LAU-01

Identifier Type: -

Identifier Source: org_study_id